Tirzepatide 20mg | Dual Agonist Research Peptide

Tirzepatide 20mg is a next-generation research peptide recognized for its unique dual agonist activity targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual mechanism has made it a major focus in metabolic and endocrine research.

In laboratory settings, tirzepatide is studied for its potential influence on insulin sensitivity, glucose regulation, and appetite signaling pathways. Its ability to act on two incretin receptors simultaneously differentiates it from traditional single-pathway compounds.

Researchers are particularly interested in tirzepatide for its potential to:

• Support studies on appetite suppression and satiety signaling

• Influence body weight and fat mass regulation

• Improve glucose metabolism and insulin response

• Explore dual incretin receptor mechanisms (GIP + GLP-1)

• Investigate effects on metabolic efficiency and energy balance

This compound has gained significant attention due to its role in advancing research surrounding obesity, metabolic disorders, and endocrine system regulation.

 Product Specifications

• Compound: Tirzepatide

• Quantity: 20mg per vial

• Purity: ≥99% (research-grade standard)

• Appearance: Lyophilized white powder

• Storage: Store in a cool, dry environment

• Stability: Maintain proper storage conditions before and after reconstitution

 Important Notice

This product is intended strictly for research purposes only.